Incyte (INCY) Gains from Investment Securities (2016 - 2026)
Incyte's (INCY) quarterly Gains from Investment Securities came in at $2.5 million in Q2 2026, down 89.02% YoY from $22.8 million in Q2 2025, and up 1587.5% on a QoQ basis from -$168000.0 in Q1 2026.
Analysis
Incyte (INCY) Gains from Investment Securities (2016 - 2026) Analysis & Trends
Incyte (INCY) has 11 years of Gains from Investment Securities data on file, last reported at $2.5 million in Q2 2026.
- Quarterly Gains from Investment Securities fell 89.02% year-over-year to $2.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$38.1 million (down 171.01% YoY) and the FY2025 annual result came in at -$6.1 million, down 130.95% from the prior year.
- Gains from Investment Securities improved to $2.5 million in Q2 2026, from -$168000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $24.3 million in Q4 2022 to a low of -$28.3 million in Q4 2025.
- A 5-year average of $3.2 million and a median of $2.9 million in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities tumbled 852.34% — and 2024, when it soared 5595.31%.
- Tracing INCY's Gains from Investment Securities over 5 years: stood at $24.3 million in 2022, then tumbled by 38.15% to $15.1 million in 2023, then plunged by 126.86% to -$4.0 million in 2024, then tumbled by 598.76% to -$28.3 million in 2025, then surged by 108.84% to $2.5 million in 2026.
- The last three Gains from Investment Securities figures came in at $2.5 million (Q2 2026), -$168000.0 (Q1 2026), and -$28.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Incyte | 25.65 Bn | 21.11 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Mar 31, 2026 | -168,000.00 |
| Dec 31, 2025 | -28.26 Mn |
| Sep 30, 2025 | -12.20 Mn |
| Jun 30, 2025 | 22.76 Mn |
| Mar 31, 2025 | 11.57 Mn |
| Dec 31, 2024 | -4.04 Mn |
| Sep 30, 2024 | 23.41 Mn |
| Jun 30, 2024 | 893,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Dec 31, 2023 | 15.06 Mn |
| Sep 30, 2023 | -426,000.00 |
| Jun 30, 2023 | 8.37 Mn |
| Mar 31, 2023 | 6.20 Mn |
| Dec 31, 2022 | 24.35 Mn |
| Sep 30, 2022 | -21.89 Mn |
| Jun 30, 2022 | 3.31 Mn |
| Mar 31, 2022 | 6.38 Mn |
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 2.91 Mn |